**Chapter 6**

*Medical Isotopes*

research, 2015. **59**.

2012. **39**(5): p. 652-65.

2018. **4**(11): p. 1635-1644.

[59] Xu, Z., et al., *(18)*

2011. **153**(3): p. 198.

*neoplasms*. Elsevier.

94969-94979.

[55] Cornell, R. and N. Ridgway, *CTP: phosphocholine cytidylyltransferase: Function, Regulation, and Structure of an amphitropic enzyme required for membrane biogenesis.* Progress in lipid

[65] Shields, A.F., *PET imaging of tumor growth: not as easy as it looks.* Clinical cancer research, 2012. **18**(5): p.

[66] Chen, X. and S. Wong, *Cancer theranostics*. 2014: Academic Press.

[68] Sun, H., et al., *Imaging DNA synthesis with [18 F] FMAU and positron emission tomography in patients with cancer.* European journal of nuclear medicine and molecular imaging, 2005.

[69] Patel, Y.C., et al., *The somatostatin receptor family.* Life sciences, 1995.

[70] Fani, M., P.K. Peitl, and I. Velikyan, *Current status of radiopharmaceuticals for the theranostics of neuroendocrine neoplasms.* Pharmaceuticals, 2017. **10**(1):

[71] Virgolini, I., et al., *Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829.* Cancer Research, 1998. **58**(9): p.

[72] Virgolini, I., et al., *Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.* Cancer research,

[73] Horti, A.G., et al., *18F-ASEM, a radiolabeled antagonist for imaging the α7-nicotinic acetylcholine receptor with PET.* Journal of Nuclear Medicine, 2014.

[74] Pérez-Medina, C., et al., *PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein* 

*nanoparticles.* Journal of Nuclear Medicine, 2015. **56**(8): p. 1272-1277.

[67] Moreau, A., et al., *Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma.* Frontiers in Oncology,

1189-1191.

2019. **9**.

**32**(1): p. 15-22.

p. 30.

1850-1859.

1994. **54**(3): p. 690-700.

**55**(4): p. 672-677.

**57**(13): p. 1249-1265.

[56] Spick, C., K. Herrmann, and J. Czernin, *Evaluation of prostate cancer with 11C-Acetate PET/CT.* Journal of Nuclear Medicine, 2016. **57**: p. 30S–37S.

[57] Smith, G., et al., *Synthesis and evaluation of nucleoside radiotracers for imaging proliferation.* Nucl Med Biol,

[58] Zhang, Z., et al., *Positron Emission Tomography Imaging with 2-[(18) F]F- p-Aminobenzoic Acid Detects Staphylococcus aureus Infections and Monitors Drug Response.* ACS Infect Dis,

*F-Fluoromisonidazole in tumor hypoxia imaging.* Oncotarget, 2017. **8**(55): p.

[60] Bae, Y.H. and K. Park, *Targeted drug delivery to tumors: myths, reality and possibility.* Journal of controlled release,

[61] Livingston, R.B., et al., *In vitro determination of thymidine-3H labeling index in human solid tumors.* Cancer research, 1974. **34**(6): p. 1376-1380.

[62] Abdalla, A.M.E., et al., *Engineered nanoparticles: thrombotic events in cancer.* Nanoscale, 2014. **6**(23): p. 14141-14152.

[63] Winchell, H.S. *Mechanisms for localization of radiopharmaceuticals in* 

[64] Wells, P., et al., *Assessment of proliferation in vivo using 2-[11C]* 

*thymidine positron emission tomography in advanced intra-abdominal malignancies.* Cancer research, 2002. **62**(20): p.

**116**

5698-5702.
